DNLI · Denali Therapeutics Inc
United States · RS rating 44 · As of 2026-11-03
| Price | 19.45 USD |
|---|---|
| 1-day change | +3.1% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 51 / 31 / 68 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 29 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +1.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +28.5% |
| Market cap (USD) | $3.1B |